Mechanisms and management of growth impairment in children affected by inflammatory bowel disease

References

• Sawczenko A, Sandhu BK, Logan RF et al. Prospective survey of childhood inflammatory bowel disease in the British Isles. Lancet 357(9262), 1093–1094 (2001).
   PubMed Web of Science ®Google Scholar
• Benchimol EI, Guttmann A, Griffiths AM et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut 58(11), 1490–1497 (2009).
   PubMed Web of Science ®Google Scholar
• Kugathasan S, Judd RH, Hoffmann RG et al.; Wisconsin Pediatric Inflammatory Bowel Disease Alliance. Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J. Pediatr. 143(4), 525–531 (2003).
   PubMed Web of Science ®Google Scholar
• Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 55(6), 749–753 (2006).
   PubMed Web of Science ®Google Scholar
• Hildebrand H, Karlberg J, Kristiansson B. Longitudinal growth in children and adolescents with inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 18(2), 165–173 (1994).
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Rosa J, Aiges H, Daum F. Growth failure in pediatric inflammatory bowel disease. J. Pediatr. Gastroenterol. Nutr. 16(4), 373–380 (1993).
   PubMed Web of Science ®Google Scholar
• Sawczenko A, Ballinger AB, Savage MO, Sanderson IR. Clinical features affecting final adult height in patients with pediatric-onset Crohn’s disease. Pediatrics 118(1), 124–129 (2006).
   PubMed Web of Science ®Google Scholar
• Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of Crohn’s disease. Gastroenterology 95(6), 1523–1527 (1988).
   PubMed Web of Science ®Google Scholar
• Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch. Dis. Child. 88(11), 995–1000 (2003).
   PubMed Web of Science ®Google Scholar
• Cabrera-Abreu JC, Davies P, Matek Z, Murphy MS. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch. Dis. Child. 89(1), 69–71 (2004).
   PubMed Web of Science ®Google Scholar
• Vortia E, Kay M, Wyllie R. The role of growth hormone and insulin-like growth factor-1 in Crohn’s disease: implications for therapeutic use of human growth hormone in pediatric patients. Curr. Opin. Pediatr. 23(5), 545–551 (2011).
   PubMed Web of Science ®Google Scholar
• Herrington J, Smit LS, Schwartz J, Carter-Su C. The role of STAT proteins in growth hormone signaling. Oncogene 19(21), 2585–2597 (2000).
   PubMed Web of Science ®Google Scholar
• Frank SJ, Messina JL, Baumann G, Black RA, Bertics PJ. Insights into modulation of (and by) growth hormone signaling. J. Lab. Clin. Med. 136(1), 14–20 (2000).
   PubMedGoogle Scholar
• Teglund S, McKay C, Schuetz E et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell 93(5), 841–850 (1998).
   PubMed Web of Science ®Google Scholar
• Ram PA, Waxman DJ. SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J. Biol. Chem. 274(50), 35553–35561 (1999).
   PubMed Web of Science ®Google Scholar
• Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16(1), 3–34 (1995).
   PubMed Web of Science ®Google Scholar
• Underwood LE, Thissen JP, Lemozy S, Ketelslegers JM, Clemmons DR. Hormonal and nutritional regulation of IGF-I and its binding proteins. Horm. Res. 42(4–5), 145–151 (1994).
   PubMed Web of Science ®Google Scholar
• Isaksson OG, Lindahl A, Nilsson A, Isgaard J. Mechanism of the stimulatory effect of growth hormone on longitudinal bone growth. Endocr. Rev. 8(4), 426–438 (1987).
   PubMed Web of Science ®Google Scholar
• Walters TD, Griffiths AM. Mechanisms of growth impairment in pediatric Crohn’s disease. Nat. Rev. Gastroenterol. Hepatol. 6(9), 513–523 (2009).
   PubMed Web of Science ®Google Scholar
• Cutler GB Jr. The role of estrogen in bone growth and maturation during childhood and adolescence. J. Steroid Biochem. Mol. Biol. 61(3–6), 141–144 (1997).
   PubMed Web of Science ®Google Scholar
• Griffiths AM, Nguyen P, Smith C, MacMillan JH, Sherman PM. Growth and clinical course of children with Crohn’s disease. Gut 34(7), 939–943 (1993).
   PubMed Web of Science ®Google Scholar
• Wine E, Reif SS, Leshinsky-Silver E et al. Pediatric Crohn’s disease and growth retardation: the role of genotype, phenotype, and disease severity. Pediatrics 114(5), 1281–1286 (2004).
   PubMedGoogle Scholar
• Kleinman RE, Baldassano RN, Caplan A et al.; North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. Nutrition support for pediatric patients with inflammatory bowel disease: a clinical report of the North American Society for Pediatric Gastroenterology, Hepatology And Nutrition. J. Pediatr. Gastroenterol. Nutr. 39(1), 15–27 (2004).
   PubMed Web of Science ®Google Scholar
• Motil KJ, Grand RJ, Davis-Kraft L, Ferlic LL, Smith EO. Growth failure in children with inflammatory bowel disease: a prospective study. Gastroenterology 105(3), 681–691 (1993).
   PubMed Web of Science ®Google Scholar
• Kirschner BS, Klich JR, Kalman SS, deFavaro MV, Rosenberg IH. Reversal of growth retardation in Crohn’s disease with therapy emphasizing oral nutritional restitution. Gastroenterology 80(1), 10–15 (1981).
   PubMed Web of Science ®Google Scholar
• Gavin J, Anderson CE, Bremner AR, Beattie RM. Energy intakes of children with Crohn’s disease treated with enteral nutrition as primary therapy. J. Hum. Nutr. Diet. 18(5), 337–342 (2005).
   PubMedGoogle Scholar
• Sitrin MD. Nutrition support in inflammatory bowel disease. Nutr. Clin. Pract. 7(2), 53–60 (1992).
   PubMedGoogle Scholar
• Smith WJ, Underwood LE, Clemmons DR. Effects of caloric or protein restriction on insulin-like growth factor-I (IGF-I) and IGF-binding proteins in children and adults. J. Clin. Endocrinol. Metab. 80(2), 443–449 (1995).
   PubMed Web of Science ®Google Scholar
• Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. Gastroenterol. Hepatol. 3(7), 390–407 (2006).
   PubMedGoogle Scholar
• McCaffery TD, Nasr K, Lawrence AM, Kirsner JB. Sever growth retardation in children with inflammatory bowel disease. Pediatr. 45(3), 386–393 (1970).
   PubMed Web of Science ®Google Scholar
• Thomas AG, Holly JM, Taylor F, Miller V. Insulin like growth factor-I, insulin like growth factor binding protein-1, and insulin in childhood Crohn’s disease. Gut 34(7), 944–947 (1993).
   PubMed Web of Science ®Google Scholar
• Tenore A, Berman WF, Parks JS, Bongiovanni AM. Basal and stimulated serum growth hormone concentrations in inflammatory bowel disease. J. Clin. Endocrinol. Metab. 44(4), 622–628 (1977).
   PubMed Web of Science ®Google Scholar
• Chong SK, Grossman A, Walker-Smith JA, Rees LH. Endocrine dysfunction in children with Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. 3(4), 529–534 (1984).
   PubMed Web of Science ®Google Scholar
• Wong SC, Smyth A, McNeill E et al. The growth hormone insulin-like growth factor 1 axis in children and adolescents with inflammatory bowel disease and growth retardation. Clin. Endocrinol. (Oxf.) 73(2), 220–228 (2010).
   PubMed Web of Science ®Google Scholar
• Street ME, de’Angelis G, Camacho-Hübner C et al. Relationships between serum IGF-1, IGFBP-2, interleukin-1β and interleukin-6 in inflammatory bowel disease. Horm. Res. 61(4), 159–164 (2004).
   PubMedGoogle Scholar
• DiFedele LM, He J, Bonkowski EL et al. Tumor necrosis factor-α blockade restores growth hormone signaling in murine colitis. Gastroenterology 128(5), 1278–1291 (2005).
   PubMed Web of Science ®Google Scholar
• Malik S, Wong SC, Bishop J et al. Improvement in growth of children with Crohn disease following anti-TNF-α therapy can be independent of pubertal progress and glucocorticoid reduction. J. Pediatr. Gastroenterol. Nutr. 52(1), 31–37 (2011).
   PubMed Web of Science ®Google Scholar
• Vespasiani Gentilucci U, Caviglia R, Picardi A et al. Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Aliment. Pharmacol. Ther. 21(9), 1063–1071 (2005).
   PubMedGoogle Scholar
• Denson LA, Held MA, Menon RK, Frank SJ, Parlow AF, Arnold DL. Interleukin-6 inhibits hepatic growth hormone signaling via upregulation of Cis and Socs-3. Am. J. Physiol. Gastrointest. Liver Physiol. 284(4), G646–G654 (2003).
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Meazza C, Oliveri M et al. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142(11), 4818–4826 (2001).
   PubMed Web of Science ®Google Scholar
• Ram PA, Waxman DJ. Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J. Biol. Chem. 275(50), 39487–39496 (2000).
   PubMed Web of Science ®Google Scholar
• Wang X, Jiang J, Warram J et al. Endotoxin-induced proteolytic reduction in hepatic growth hormone (GH) receptor: a novel mechanism for GH insensitivity. Mol. Endocrinol. 22(6), 1427–1437 (2008).
   PubMed Web of Science ®Google Scholar
• Hales DB, Diemer T, Hales KH. Role of cytokines in testicular function. Endocrine 10(3), 201–217 (1999).
   PubMed Web of Science ®Google Scholar
• Terranova PF, Rice VM. Review: cytokine involvement in ovarian processes. Am. J. Reprod. Immunol. 37(1), 50–63 (1997).
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Rucci N, Del Fattore A et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 54(11), 3551–3563 (2006).
   PubMed Web of Science ®Google Scholar
• Tamura T, Udagawa N, Takahashi N et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc. Natl Acad. Sci. USA 90(24), 11924–11928 (1993).
   PubMed Web of Science ®Google Scholar
• Azooz OG, Farthing MJ, Savage MO, Ballinger AB. Delayed puberty and response to testosterone in a rat model of colitis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 281(5), R1483–R1491 (2001).
   PubMed Web of Science ®Google Scholar
• Ferguson A, Sedgwick DM. Juvenile onset inflammatory bowel disease: height and body mass index in adult life. BMJ 308(6939), 1259–1263 (1994).
   PubMed Web of Science ®Google Scholar
• Brain CE, Savage MO. Growth and puberty in chronic inflammatory bowel disease. Baillieres Clin. Gastroenterol. 8(1), 83–100 (1994).
   PubMedGoogle Scholar
• Ezri J, Marques-Vidal P, Nydegger A. Impact of disease and treatments on growth and puberty of pediatric patients with inflammatory bowel disease. Digestion 85(4), 308–319 (2012).
   PubMed Web of Science ®Google Scholar
• Sawczenko A, Azooz O, Paraszczuk J et al. Intestinal inflammation-induced growth retardation acts through IL-6 in rats and depends on the -174 IL-6 G/C polymorphism in children. Proc. Natl Acad. Sci. USA 102(37), 13260–13265 (2005).
   PubMed Web of Science ®Google Scholar
• Levine A, Shamir R, Wine E et al. TNF promoter polymorphisms and modulation of growth retardation and disease severity in pediatric Crohn’s disease. Am. J. Gastroenterol. 100(7), 1598–1604 (2005).
   PubMedGoogle Scholar
• Russell RK, Drummond HE, Nimmo ER et al. Analysis of the influence of OCTN1/2 variants within the IBD5 locus on disease susceptibility and growth indices in early onset inflammatory bowel disease. Gut 55(8), 1114–1123 (2006).
   PubMed Web of Science ®Google Scholar
• Beattie RM, Nicholls SW, Domizio P, Williams CB, Walker-Smith JA. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J. Pediatr. Gastroenterol. Nutr. 22(4), 373–379 (1996).
   PubMedGoogle Scholar
• Giustina A, Wehrenberg WB. The role of glucocorticoids in the regulation of growth hormone secretion: mechanisms and clinical significance. Trends Endocrinol. Metab. 3(8), 306–311 (1992).
   PubMed Web of Science ®Google Scholar
• Kritsch KR, Murali S, Adamo ML, Ney DM. Dexamethasone decreases serum and liver IGF-I and maintains liver IGF-I mRNA in parenterally fed rats. Am. J. Physiol. Regul. Integr. Comp. Physiol. 282(2), R528–R536 (2002).
   Google Scholar
• Jux C, Leiber K, Hügel U et al. Dexamethasone impairs growth hormone (GH)-stimulated growth by suppression of local insulin-like growth factor (IGF)-I production and expression of GH- and IGF-I-receptor in cultured rat chondrocytes. Endocrinology 139(7), 3296–3305 (1998).
   PubMed Web of Science ®Google Scholar
• Uchida K, Araki T, Toiyama Y et al. Preoperative steroid-related complications in Japanese pediatric patients with ulcerative colitis. Dis. Colon Rectum 49(1), 74–79 (2006).
   PubMed Web of Science ®Google Scholar
• Uchida K, Araki T, Inoue M et al. Poor catch-up growth after proctocolectomy in pediatric patients with ulcerative colitis receiving prolonged steroid therapy. Pediatr. Surg. Int. 26(4), 373–377 (2010).
   PubMed Web of Science ®Google Scholar
• Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J. Pediatr. Gastroenterol. Nutr. 31(1), 8–15 (2000).
   PubMed Web of Science ®Google Scholar
• Bannerjee K, Camacho-Hubner C, Babinska K et al. Anti-inflammatory and growth-stimulating effects precede nutritional restitution during enteral feeding in Crohn’s disease. J. Pediatr. Gatroenterol. Nutr. 38(3), 270–275 (2004).
   PubMed Web of Science ®Google Scholar
• Borrelli O, Cordischi L, Cirulli M et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn’s disease: a randomized controlled open-label trial. Clin. Gastroenterol. Hepatol. 4(6), 744–753 (2006).
   PubMed Web of Science ®Google Scholar
• Fell JM, Paintin M, Arnaud-Battandier F et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment. Pharmacol. Ther. 14(3), 281–289 (2000).
   PubMed Web of Science ®Google Scholar
• Laharie D, Reffet A, Belleannée G et al. Mucosal healing with methotrexate in Crohn’s disease: a prospective comparative study with azathioprine and infliximab. Aliment. Pharmacol. Ther. 33(6), 714–721 (2011).
   PubMed Web of Science ®Google Scholar
• Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 115(4), 813–821 (1998).
   PubMed Web of Science ®Google Scholar
• Hyams JS, Lerer T, Griffiths A et al.; Pediatric Inflammatory Bowel Disease Collaborative Research Group. Long-term outcome of maintenance infliximab therapy in children with Crohn’s disease. Inflamm. Bowel Dis. 15(6), 816–822 (2009).
   PubMed Web of Science ®Google Scholar
• Borrelli O, Bascietto C, Viola F et al. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn’s disease. Dig. Liver Dis. 36(5), 342–347 (2004).
   PubMedGoogle Scholar
• Sentongo TA, Semeao EJ, Piccoli DA, Stallings VA, Zemel BS. Growth, body composition, and nutritional status in children and adolescents with Crohn’s disease. J. Pediatr. Gastroenterol. Nutr. 31(1), 33–40 (2000).
   PubMed Web of Science ®Google Scholar
• Grupta N, Lusting RH, Kohn MA, McCracken M, Vittinghoff E. Sex differences in statural growth impairment in Crohn’s disease: role of IGF-I. Inflamm. Bowel Dis. 17(11), 2318–2325 (2011).
   PubMedGoogle Scholar
• Heuschkel R, Salvestrini C, Beattie RM, Hildebrand H, Walters T, Griffiths A. Guidelines for the management of growth failure in childhood inflammatory bowel disease. Inflamm. Bowel Dis. 14(6), 839–849 (2008).
   PubMed Web of Science ®Google Scholar
• McCaffery TD Jr, Nasr K, Lawrence AM, Kirsner JB. Effect of administered human growth hormone on growth retardation in inflammatory bowel disease. Am. J. Dig. Dis. 19(5), 411–416 (1974).
   PubMedGoogle Scholar
• Henker J. Therapy with recombinant growth hormone in children with Crohn disease and growth failure. Eur. J. Pediatr. 155(12), 1066–1067 (1996).
   PubMedGoogle Scholar
• Heyman MB, Garnett EA, Wojcicki J et al. Growth hormone treatment for growth failure in pediatric patients with Crohn’s disease. J. Pediatr. 153(5), 651–658, 658.e1 (2008).
   PubMedGoogle Scholar
• Wong SC, Hassan K, McGrogan P, Weaver LT, Ahmed SF. The effects of recombinant human growth hormone on linear growth in children with Crohn’s disease and short stature. J. Pediatr. Endocrinol. Metab. 20(12), 1315–1324 (2007).
   PubMedGoogle Scholar
• Calenda KA, Schornagel IL, Sadeghi-Nejad A, Grand RJ. Effect of recombinant growth hormone treatment on children with Crohn’s disease and short stature: a pilot study. Inflamm. Bowel Dis. 11(5), 435–441 (2005).
   PubMed Web of Science ®Google Scholar
• Denson LA, Kim MO, Bezold R et al. A randomized controlled trial of growth hormone in active pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 51(2), 130–139 (2010).
   PubMedGoogle Scholar
• Wong SC, Kumar P, Galloway PJ et al. A preliminary trial of the effect of recombinant human growth hormone on short-term linear growth and glucose homeostasis in children with Crohn’s disease. Clin. Endocrinol. (Oxf.) 74(5), 599–607 (2011).
   PubMedGoogle Scholar
• Mauras N, George D, Evans J et al. Growth hormone has anabolic effects in glucocorticosteroid-dependent children with inflammatory bowel disease: a pilot study. Metab. Clin. Exp. 51(1), 127–135 (2002).
   PubMed Web of Science ®Google Scholar
• Rizzello F, Gionchetti P, D’Arienzo A et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment. Pharmacol. Ther. 16(6), 1109–1116 (2002).
   PubMed Web of Science ®Google Scholar
• Manguso F, Balzano A. Meta-analysis: the efficacy of rectal beclomethasone dipropionate vs. 5-aminosalicylic acid in mild to moderate distal ulcerative colitis. Aliment. Pharmacol. Ther. 26(1), 21–29 (2007).
   PubMed Web of Science ®Google Scholar
• Romano C, Famiani A, Comito D, Rossi P, Raffa V, Fries W. Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine. J. Pediatr. Gastroenterol. Nutr. 50(4), 385–389 (2010).
   PubMedGoogle Scholar
• D’Haens GR, Kovács A, Vergauwe P et al. Clinical trial: preliminary efficacy and safety study of a new Budesonide-MMX® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis. J. Crohns Colitis 4(2), 153–160 (2010).
   PubMed Web of Science ®Google Scholar